We are live on ! Find out more
CMMB icon

Chemomab Therapeutics
CMMB

12 hedge funds and large institutions have $3.34M invested in Chemomab Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.25% less ownership

Funds ownership: 26.26% → 23.01% (-3.2%)

14% less funds holding

Funds holding: 14 → 12 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

99% less capital inflows, than outflows

Capital inflows: $4.74K | Capital outflows: $574K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$4.74K

Top Sellers

Rank Fund Capital Flow
1
Cormorant Asset Management
Cormorant Asset Management
Massachusetts
-$458K
2
Two Sigma Investments
Two Sigma Investments
New York
-$48.1K
3
Ikarian Capital
Ikarian Capital
Texas
-$36.8K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$18.8K
5
Morgan Stanley
Morgan Stanley
New York
-$12.1K

CMMB Hedge Fund Activity: Q2 2023 in Review

12 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2023, worth a combined $3.34M — down 27% from $4.58M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CMMB and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.

The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $4.74K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $458K sold.

  • 12 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2023, down from 14 in Q1 2023.
  • Funds reported $3.34M of Chemomab Therapeutics stock for Q2 2023, down 27% quarter-over-quarter.
  • 1 fund opened new Chemomab Therapeutics positions in Q2 2023 and 3 closed out, a net change of -2 holders.
  • The largest Chemomab Therapeutics buyer in Q2 2023 was RhumbLine Advisers, an estimated $4.74K added.
  • The largest Chemomab Therapeutics seller in Q2 2023 was Cormorant Asset Management, an estimated $458K sold.

Based on aggregated 13F filings for Q2 2023.